FHD-286 in Subjects With Metastatic Uveal Melanoma

Summary

This Phase 1, multicenter, open-label, dose escalation and expansion study is designed to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary clinical activity of FHD-286 oral monotherapy in subjects with metastatic Uveal Melanoma (UM).

Timeline

Start

2021-05-11

Primary completion

2023-11-30

Completion

2023-11-30

Outcome

Outcome not reported

Stopped (Business): “Sponsor terminated the study for business reasons.”

Drugs

Indications